Cellectis SA (CLLS)

2.99 +0.06 (+2.05%) USD  |  NASDAQ  |  Jun 09, 14:00
More

Cellectis SG&A Expense (Quarterly) : 5.610M for March 31, 2026

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for CLLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
DBV Technologies SA 15.36M
Akari Therapeutics Plc 2.165M
Amarin Corp. Plc 19.35M
Grifols SA 328.75M
Autolus Therapeutics Plc 39.89M